GlassScriptPhysician profile
Jared Alexander Marquardt
NPI 1235541756
$3,099.98
in general payments reported to CMS, 2019-2025
36 companies · $206 in 2025
The $206 reported for 2025 was more than what 83% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $816 · 2020: $420 · 2021: $615 · 2022: $400 · 2023: $406 · 2024: $236 · 2025: $206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $849.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $848.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $468.89 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $359.68 | 2019-2023 | Otezla, Repatha |
| Pfizer INC. | $259.10 | 2019-2024 | |
| Abbvie INC. | $206.38 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $201.08 | 2019-2023 | Verquvo, Belsomra |
| Janssen Pharmaceuticals, INC | $185.35 | 2019-2021 | |
| Astellas Pharma US INC | $168.72 | 2019-2023 | Veozah |
| Sanofi-Aventis U.S. LLC | $160.58 | 2019-2022 | |
| Lilly USA, LLC | $153.94 | 2019-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.74 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $84.01 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $79.55 | 2024-2025 | Voquezna |
| Lundbeck LLC | $72.76 | 2024 | Rexulti |
| Mylan Specialty L.P. | $58.16 | 2020-2023 | Yupelri |
| Organogenesis INC. | $50.21 | 2021-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $49.80 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $42.01 | 2019-2025 | Eliquis |
| Sanofi Pasteur INC. | $39.78 | 2023 | |
| Incyte Corporation | $31.50 | 2022 | |
| Myriad Women'S Health, INC. | $30.56 | 2023 | Myrisk |
| Biohaven Pharmaceutical Holding Company LTD. | $30.01 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.04 | 2022-2024 | |
| Philips North America LLC | $21.60 | 2019 | |
| Amarin Pharma, INC. | $19.98 | 2020 | |
| Xeris Pharmaceuticals, INC. | $19.33 | 2021 | |
| Cepheid | $17.56 | 2024 | |
| Exact Sciences Corporation | $16.86 | 2023 | Cologuard Collection Kit |
| Smith+Nephew, INC. | $16.42 | 2021 | |
| Glaxosmithkline, LLC. | $14.04 | 2021 | |
| Medtronic USA, INC. | $14.03 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.87 | 2025 | Caplyta |
| Ultragenyx Pharmaceutical INC. | $12.61 | 2022 | |
| Genzyme Corporation | $12.29 | 2021 | |
| Sunovion Pharmaceuticals INC. | $12.01 | 2019 | |
| Tactile Systems Technology INC | $11.83 | 2019 | |
| Boston Scientific Corporation | $11.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Marquardt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.